loading
Ars Pharmaceuticals Inc stock is traded at $14.32, with a volume of 2.46M. It is down -3.76% in the last 24 hours and up +15.86% over the past month. ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
See More
Previous Close:
$14.88
Open:
$14.68
24h Volume:
2.46M
Relative Volume:
1.48
Market Cap:
$1.42B
Revenue:
-
Net Income/Loss:
$-44.84M
P/E Ratio:
-30.47
EPS:
-0.47
Net Cash Flow:
$-44.23M
1W Performance:
-1.04%
1M Performance:
+15.86%
6M Performance:
-14.35%
1Y Performance:
+69.07%
1-Day Range:
Value
$13.77
$14.92
1-Week Range:
Value
$13.77
$15.12
52-Week Range:
Value
$7.55
$18.51

Ars Pharmaceuticals Inc Stock (SPRY) Company Profile

Name
Name
Ars Pharmaceuticals Inc
Name
Phone
858-771-9307
Name
Address
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Name
Employee
160
Name
Twitter
Name
Next Earnings Date
2024-12-13
Name
Latest SEC Filings
Name
SPRY's Discussions on Twitter

Compare SPRY with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
SPRY
Ars Pharmaceuticals Inc
14.32 1.42B 0 -44.84M -44.23M -0.47
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-07-25 Initiated Scotiabank Sector Outperform
Feb-10-25 Initiated Oppenheimer Outperform
Aug-20-24 Initiated Cantor Fitzgerald Overweight
Aug-13-24 Upgrade Raymond James Outperform → Strong Buy
Aug-12-24 Reiterated Leerink Partners Outperform
Jul-25-24 Initiated Raymond James Outperform
Mar-05-24 Upgrade Leerink Partners Market Perform → Outperform
Feb-20-24 Upgrade William Blair Mkt Perform → Outperform
Sep-20-23 Downgrade William Blair Outperform → Mkt Perform
Jan-31-23 Initiated Wedbush Outperform
Jan-03-23 Initiated William Blair Outperform
Dec-13-22 Initiated SVB Leerink Outperform
View All

Ars Pharmaceuticals Inc Stock (SPRY) Latest News

pulisher
Apr 20, 2025

(SPRY) On The My Stocks Page - news.stocktradersdaily.com

Apr 20, 2025
pulisher
Apr 08, 2025

ARS Pharmaceuticals director Laura Shawver sells $615,074 in stock By Investing.com - Investing.com India

Apr 08, 2025
pulisher
Apr 08, 2025

ARS Pharmaceuticals director Laura Shawver sells $615,074 in stock - Investing.com Australia

Apr 08, 2025
pulisher
Apr 05, 2025

ARS Pharmaceuticals (SPRY): Among Unstoppable Stocks That Could Double Your Money - Insider Monkey

Apr 05, 2025
pulisher
Apr 04, 2025

How the (SPRY) price action is used to our Advantage - news.stocktradersdaily.com

Apr 04, 2025
pulisher
Apr 04, 2025

10 Unstoppable Stocks That Could Double Your Money - Insider Monkey

Apr 04, 2025
pulisher
Apr 03, 2025

High Insider Ownership Growth Stocks To Know In April 2025 - simplywall.st

Apr 03, 2025
pulisher
Apr 03, 2025

Revenues Not Telling The Story For ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) After Shares Rise 28% - simplywall.st

Apr 03, 2025
pulisher
Apr 03, 2025

ARS Pharmaceuticals, Inc. (SPRY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire

Apr 03, 2025
pulisher
Mar 26, 2025

Downgrade: Here's How Analysts See ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Performing In The Near Term - simplywall.st

Mar 26, 2025
pulisher
Mar 26, 2025

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analysts Are Reducing Their Forecasts For This Year - Yahoo Finance

Mar 26, 2025
pulisher
Mar 25, 2025

Long Term Trading Analysis for (SPRY) - news.stocktradersdaily.com

Mar 25, 2025
pulisher
Mar 24, 2025

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q4 2024 Earnings Call Transcript - MSN

Mar 24, 2025
pulisher
Mar 24, 2025

Raymond James lifts ARS Pharmaceuticals price target to $32 - Investing.com

Mar 24, 2025
pulisher
Mar 24, 2025

Raymond James lifts ARS Pharmaceuticals price target to $32 By Investing.com - Investing.com UK

Mar 24, 2025
pulisher
Mar 24, 2025

ARS Pharmaceuticals outlines 2025 growth strategy with neffy commercialization and global expansion - MSN

Mar 24, 2025
pulisher
Mar 24, 2025

Neffy 1 mg Approved to Treat Severe Allergic Reactions in Younger Children - Pulmonology Advisor

Mar 24, 2025
pulisher
Mar 22, 2025

ARS Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - MSN

Mar 22, 2025
pulisher
Mar 21, 2025

Ars pharmaceuticals chief commercial officer Eric Karas sells $140,000 in stock - Investing.com Australia

Mar 21, 2025
pulisher
Mar 21, 2025

Ars pharmaceuticals chief commercial officer Eric Karas sells $140,000 in stock By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

neffy From ARS Pharmaceuticals, Inc - Pharmacy Times

Mar 21, 2025
pulisher
Mar 21, 2025

ARS Pharmaceuticals Full Year 2024 Earnings: Beats Expectations - Yahoo Finance

Mar 21, 2025
pulisher
Mar 21, 2025

ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

Decoding ARS Pharmaceuticals Inc (SPRY): A Strategic SWOT Insigh - GuruFocus

Mar 21, 2025
pulisher
Mar 21, 2025

ARS Pharmaceuticals Reports Strong 2024 Financial Results - TipRanks

Mar 21, 2025
pulisher
Mar 20, 2025

Raymond James maintains $28 target on ARS Pharma stock By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

ARS Pharmaceuticals: Surging On Solid EarningsBut Real Challenges Await (NASDAQ:SPRY) - Seeking Alpha

Mar 20, 2025
pulisher
Mar 20, 2025

Raymond James maintains $28 target on ARS Pharma stock - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why. - MSN

Mar 20, 2025
pulisher
Mar 20, 2025

Earnings call transcript: ARS Pharmaceuticals Q4 2024 earnings beat expectations - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewswire

Mar 20, 2025
pulisher
Mar 20, 2025

Earnings call transcript: ARS Pharmaceuticals Q4 2024 earnings beat expectations By Investing.com - Investing.com UK

Mar 20, 2025
pulisher
Mar 20, 2025

ARS Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Sector Update: Health Care Stocks Decline Pre-Bell Thursday - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Sector Update: Health Care - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

ARS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

ARS Pharmaceuticals Reports Q4 Results, Swings to 2024 Earnings -March 20, 2025 at 07:45 am EDT - MarketScreener

Mar 20, 2025
pulisher
Mar 20, 2025

ARS PHARMACEUTICALS Earnings Results: $SPRY Reports Quarterly Earnings - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q4 Revenue $86.6M -March 20, 2025 at 07:13 am EDT - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q4 EPS $0.48, vs. FactSet Est of $-0.04 Loss - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

ARS Pharmaceuticals, Inc. SEC 10-K Report - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

ARS Pharma Crushes Q4 with $49.9M Profit as Neffy Launch Gains Momentum - StockTitan

Mar 20, 2025
pulisher
Mar 18, 2025

This company’s epinephrine nasal spray reverses allergic reactions—no needle required - Fast Company

Mar 18, 2025
pulisher
Mar 18, 2025

From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines - Fast Company

Mar 18, 2025
pulisher
Mar 14, 2025

(SPRY) Investment Report - news.stocktradersdaily.com

Mar 14, 2025
pulisher
Mar 14, 2025

Steward Partners Investment Advisory LLC Raises Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

ARS Pharmaceuticals (SPRY) to Release Quarterly Earnings on Thursday - Defense World

Mar 13, 2025

Ars Pharmaceuticals Inc Stock (SPRY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Cap:     |  Volume (24h):